NICE issues draft “no” on daratumumab monotherapy

The National Institute for Health and Care Excellence (NICE) has issued draft negative guidance for daratumumab (Darzalex┬«) monotherapy as a treatment for relapsed and refractory myeloma patients. Although daratumumab monotherapy was granted a licence by the European Medicines Agency (EMA) based on results of two Phase II trials, the degree of uncertainty for the clinical…

Details